ALK-202 / Allink Biotherapeutics - LARVOL DELTA

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=234 | Recruiting | Sponsor: Shanghai Allink Biotherapeutics Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

Allink Biotherapeutics Raises $42M Series A Financing to Accelerate Global Development of Bispecific Antibody and ADC Pipeline (PRNewswire) - "The Series A financing proceeds will be deployed to advance: Global clinical development of lead candidates ALK201 and ALK202 through Phase 1 studies in Australia, the United States and China; Enrichment of current portfolio by developing multiple highly competitive new assets in oncology and immunology; Further development of the company's proprietary bispecific antibody and ADC technology platform; Global footprint expansion to achieve world prominence."

Financing • Solid Tumor

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=234 | Not yet recruiting | Sponsor: Shanghai Allink Biotherapeutics Co., Ltd.

Metastases • New P1 trial • Oncology • Solid Tumor

Anlinke: ALK202 starts 234 cases of Phase I clinical trial [Google translation] (bydrug.pharmcube.com) - "The Phase I clinical trial plans to enroll 234 patients with advanced solid tumors and is expected to be initially completed by the end of 2027. According to clinical registration information, ALK202 is an EGFR/cMET targeted drug. Judging from the R&D code and the competitive landscape, ALK202 is likely to be an EGFR/cMET dual-antibody ADC drug."

Trial primary completion date • Oncology • Solid Tumor